drug reactions to three or more drugs, without a known immunological mechanism [2, 3] . Thus, it is difficult in some cases to know if these nosologic entities refer to the same phenomenon. Even more confusing is to consider how single drug adverse drug reactions (ADRs) relate to a defined MDAS or MDIS case. ADRs usually affect the skin and/or mucosae (toxicoderma) [4] [5] [6] [7] [8] [9] [10] [11] [12] , and are challenging to dermatologists, toxicologists, emergency physicians, allergists and immunologists.
A better understanding of the etiopathogenic mechanisms of drug reactions is needed, and especially when these reactions are concomitant with the presence of other sequelae such as viral infections. Such non-drug reaction forces could make selected immunologic processes more complex than previously considered [5] [6] [7] [8] [9] . It is also believed that allergic drug reactions may have a genetic predisposition, and that epidemiologic factors can also play a role. We describe a case that exemplifies the complexity of adverse drug reactions.
CASE REPORT
An obese, diabetic 61 year old female presented to the dermatologist with flaccid bullae and plaques, on erythematous bases. The patient was taking Doxycycline hyclate 100 mgs caps one at day orally; Micardis HCt; oral Metformin® 850 Mgs tablets; an oral multivitamin; Symlin® SubQ, Lantus® SubQ; Novolag® SubQ. The patient described no personal or family drug allergy history. Biopsies for hematoxylin and eosin (H&E) examination, direct immunofluorescence (DIF) and immunohistochemistry (IHC) analysis were performed. After receiving the biopsy results, the patient was prescribed with econazole 1% topical cream once or twice a day, and hydrocortisone topical 2.5% lotion; the dermatologist also began working to change and/or decrease her medications in consultation with her other physicians.
MATERIALS AND METHODS
Skin biopsies were taken for histology (H&E) studies, for immunohistochemistry (IHC) and for direct immunofluorescence studies (DIF); our techniques were performed as previously described [7] [8] [9] [10] [11] [12] .
Direct immunofl uorescence (DIF)
For DIF, the skin was imbedded in optimal cutting temperature (OCT) compound for frozen-sectioning.
The skin was then incubated with primary and/or secondary antibodies. We utilized FITC conjugated rabbit antisera to human IgG, IgA, IgM, IgD, IgE, Complement/C1q, Complement/C3, Complement/ C4, Kappa light chains, Lambda light chains, albumin and fibrinogen. All of our antibodies were obtained from Dako(Carpinteria, California, USA) with the following details and exceptions. Our anti-human IgA antiserum (alpha chain) and anti-human IgM antiserum (mu chain) were obtained from Dako. Our anti-human-IgE antiserum (epsilon chain) was obtained from Vector Laboratories (Burlingame, California, USA). Our anti-human IgD antibodies were obtained from Southern Biotechnology (Birmingham, Alabama, USA), and utilized at dilutions of 1:20 to 1:40. The slides were counterstained with 4',6-diamidino-2-phenylindole(DAPI; Pierce, Rockford, Illinois, USA). We also used Texas Red conjugated Ulex europaeus agglutinin 1 (UEA) (from Vector Burlingame, CA, USA) as a vascular marker. The samples were consistently run with positive and negative controls. We classified our findings as negative (-), weakly positive (+), positive (+++) and strongly positive (++++).
IHC double staining
Our double stained IHC was performed using a double staining system; we utilized the Leica Bond Max platform autostainer with bond polymer refined Red detection DS9390, alkaline phosphatase linker polymer and fast red chromogen (red staining) as previously described [5] [6] [7] [8] [9] . We also used a bond polymer refined detection DS9800, horseradish peroxidase linked polymer and DAB chromogen (brown staining). The following antibodies were utilized from Dako: Mouse monoclonal anti-human CD4; CD8; CD15; CD68; B-cell lymphoma 2 gene (BCL-2) oncoprotein, clone 124; cyclooxygenase-2 (COX-2), clone CX-294; polyclonal rabbit anti-human vonWillembrand factor, and D2-40/podoplanin. The following antibodies were used from Novocastra (Chicago, Illinois, USA): anti-human CD4 clone 4B12; anti-human C8 Clone C8/144B, and von Willembrand factor. We counterstained the slides with hematoxylin. Positive and negative controls were consistently performed.
RESULTS

Microscopic description
A: Examination of the H&E tissue sections demonstrated diffuse, moderate epidermal spongiosis present.
A subepidermal blister was noted, with small numbers of lymphocytes and eosinophils noted within the blister lumen. Significant superficial papillary dermal edema was noted. The dermis also displayed a mild, superficial, perivascular infiltrate of lymphocytes and histiocytes; eosinophils and neutrophils are rare. No frank vasculitis was present; however, some fibrinoid alterations were seen in dermal blood vessel walls ( Fig. 1) .
Direct immunofl uorescence (DIF)
Our DIF demonstrated the following results: IgG (+, focal dermal perivascular); IgA (++, focal dermal perivascular and faint linear basement membrane zone staining) ( Fig. 1) ; IgM (+, focal dermal perivascular and focal epidermal); IgD (+, focal dermal perivascular); IgE (-); Complement/C1q (+, focal dermal perivascular); Complement/C3 (++, focal dermal perivascular, and focal epidermal); Complement/C4 (-); Kappa light chains (+, focal dermal perivascular); Lambda light chains (+, focal dermal perivascular and focal epidermal); albumin (+, focal punctate dot epidermal stratum corneum) and fibrinogen (++++, focal dermal perivascular, perieccrine and +, faint linear BMZ). Of interest was the positivity of some type of dermal cells junctions seen with fibrinogen (++) (see Fig. 1 ).
Immunohistochemistry (IHC)
D2-40 seemed to be overexpressed on lymphatic vessels in areas such as under the blister, and around hair follicles and sweat glands. Von Willembrand factor staining showed that the blood vessels in the upper dermis were somehow compartmentalized under the blister (Fig. 1) . CD15 was negative, as well as CD68. CD8 was positive only in small amounts around some upper dermal vessels. In contrast, CD4 was positive around several upper dermal blood vessels and around eccrine sweat gland ducts. BCL-2 followed the same pattern of positivity as CD4. COX-2 was very positive around the dermal blood vessels, as well as in other areas of the inflammatory infiltrate.
DISCUSSION
From the immunologic point of view, we have seen allergic skin reactions becoming more common in an aging population. These reactions involve interactions between multiple medications, and also reactions to soaps, detergents, hair dyes, shampoos, toothpastes and food preseratives [5] [6] [7] [8] [9] . Multiple simultaneous medications can alter how the body metabolizes the drugs, and also can produce alterations in the immune system. The ADR/MDAS/MDIS classifications are potentially more complex than the classic Gell and Coombs classification [13] . The Gell-Coombs classification divides drug hypersensitivity and other immune reactions into four categories, known as type I-IV reactions. In cases like ours, we see an immune response that features several units of the Gell-Coombs Our laboratory has extensive experience with skin biopsies from patients with multiple drug reactions. In many of our ADR/MDAS/MDIS cases, we note that a histologic hallmark is the presence of fibrinoid material in the superficial and deep dermal blood vessels [9] [10] [11] [12] .
The classic immune response is demonstrated by a significant anti-human-fibrinogen antibody component. In the current case, we noted that the dermal vessels demonstrated changes in their sizes and shapes; these changes could trigger deposits from the clotting cascade. We also demonstrated that both lymphatics and blood vessels were affected by these changes. We speculate that these vessels could become immunologically active by the drug reaction damage, and molecules such as inducible COX-2 could become active in these sites [14] . It also has been reported that many drug eruptions are due to T cell-mediated hypersensitivity reactions; these reactions can involve activation of multiple pro-inflammatory mechanisms, which would explain the varied manifestations. However, other allergic drug reaction immune components have also been described [15, 16] . In this context, our CD68 staining was largely negative, suggesting that significant activation of the classic antigen presenting cell pathway did not occur. Moreover, some immunologic aspects of drug reactions challenge our classical understanding of antigen processing and presentation. New immunologic hypotheses have been proposed in their study, including whether complement and/or immunoglobulins can formally alter molecules. The altered molecules could then, in theory, act as new haptens [15, 16] .
In our case, we also found that some of the cells staining with CD4 and CD8 were also positive with BCL-2; BCL-2 is considered an important anti-apoptotic protein [17] . In addition, recent discoveries have also noted that BCL2 molecules are indispensable for activation and maturation of T lymphocytes following antigen presentation [17] . One group of authors identified patient factors that could increase the risk of MDIS, in a total of 25,695 patients with documented drug intolerance. Their findings demonstrated that MDIS was associated with female gender, multiple comorbidities, and previous hospital admissions. A documented allergy to penicillin did not increase the likelihood of MDIS [2] . The cases seen in our laboratory also had shown agreement with these findings, especially relative to comorbidities and advanced patient age.
In our experience, when a multiple drug allergy syndrome and/or allergic drug reaction is being evaluated the DIF usually demonstrates significant reactivity with fibrinogen and complement. We have noted significantly less reactivity with IgG and IgA, contrary to classic autoimmune blistering diseases that often demonstrate significant deposits of these immunoglobulins, Complement/C3 and fibrinogen at the basement membrane zone. Additionally, most linear IgA deposits at the BMZ seen by DIF in adults present in allergic drug reactions [17] .
CONCLUSIONS
The approach and assessment of patients with possible ADRs/MDAS/MDIS involves taking a comprehensive drug allergy history, ruling out viral or other concomitant infections [18] , and immediately contacting other physicians that are treating the patient to work together to decrease the dosage of and/or discontinue some medications.
